3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
8
Active not recruiting
3
Terminated
2
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
3
NET
2
Endocrine
2
CNS
1
Conditions
Neuroendocrine Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Capecitabine
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Octreotide
×
NET
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled